TECH

Bio-Techne Corp. (TECH) | Rumor.io

Bio-Techne

TECH

Attention (50-day avg)0%

Attention rank (50-day avg)#4,476

Bullish sentiment (50-day avg)0%

Price to earnings ratio62.5

Market capitalization11.4B

Earnings per share1.16

Dividend yield (TTM)0.44%

Revenue (annual)1.2B

Net income (annual)181.9M

Social

What share of all stock conversation is about TECH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% new	0% 0

Jan 30

$TECH stock has surged by 3% to a new high of $500, marking its first major victory.
The article explains the recent news and developments about $TECH in a simple and easy-to-understand format.
The stock's significant increase has brought joy and excitement to investors, with some even calling it a "大発見" (big discovery).

Generated by AI

Sentiment

Of the messages about TECH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	59.69% +4.4
Bearish	—	—	—	40.31% -4.4

Jul 25

TECH has broken above its 150 EMA with strong volume, indicating a potential uptrend.
Bio-Techne Corporation, the owner of the TECH ticker, has a history of significant price increases, suggesting a possible repeat performance.
With a bounce off recent lows and a manageable downside risk, TECH presents a relatively low-risk entry point for a potential long-term run.

Generated by AI

Topics

Of the messages about TECH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	1.32%
Announcements	—	—	—	81.44%
Controversies	—	—	—	0.13%
Earnings	—	—	—	1.8%
Macro	—	—	—	3.78%
Technical Analysis	—	—	—	11.52%

Feb 2

Bio-Techne Corporation's $TECH has no utility in bioweapon development, according to a study using OpenAI's GPT-4.
FBI Director warns that Beijing-linked hackers are targeting US infrastructure, with low blows against civilians part of China's plan.
No market-relevant announcements were found in the provided social media posts.

Generated by AI

Community

Of the messages about TECH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	85.71%	19.02%
Newcomers	—	0%	14.29%	80.98%

Regulars· May 1

Bio-Techne Corporation's shares surged 17.58% after the company released its third-quarter fiscal 2024 results, with the stock trading 121% above average volume.
The results were mixed, with the company's earnings showing a decline due to market challenges, but the stock still saw a significant increase in price.
Bio-Techne Corporation's shares continued to trade above average volume, with the stock up 16.29% after the company's Q3 fiscal 2024 earnings release.

Newcomers· Jan 30

Newcomers to the stock market are finding $TECH's recent 3% increase in price to be a significant win, with one user expressing joy and excitement over the news.
Many users are discovering and sharing articles that explain $TECH's news in simple terms, making it easier for newcomers to understand the company and its stock.
One user has made a big discovery, finding that $TECH's stock price has increased by 3% to 500, and is calling it their first big win in the stock market.

Generated by AI

News

2 Cash-Producing Stocks Worth Investigating and 1 We Brush Off

Detailed price information for Lennox International (LII-N) from The Globe and Mail including charting and trades.

2d agoThe Globe and Mail

Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package

Bio-Techne Corporation (NASDAQ:TECH) shareholders voted on September 23 to approve the company’s acquisition by Merck KGaA of Darmstadt, Germany. The German group is paying $73 a share in cash, valuing the business at about $11.3 billion including debt. They also voted down the executive compensation proposal attached to the deal, which is an unusual pairing. […]

4d agoYahoo Finance

Robert V Baumgartner Exercises Options, Realizes $754K - Bio-Techne (NASDAQ:TECH)

Robert V Baumgartner, Board Member at Bio-Techne (NASDAQ:TECH), reported a large exercise of company stock options on September 24, according to a new SEC filing. What Happened: In an insider options exercise disclosed

4d agoBenzinga

Is Bio-Techne Stock Outperforming the Nasdaq?

Bio-Techne has outperformed the Nasdaq over the past year, but analysts are cautious about the stock’s prospects.

6d agoYahoo Finance

Merck KGaA (XTRA:MRK) Clears Key Acquisition Hurdle After Shareholder Approval

Merck KGaA (XTRA:MRK) has received shareholder approval from Bio-Techne investors for its planned acquisition of the US life sciences group. The vote clears a major corporate hurdle in the transaction process, with completion still subject to remaining regulatory reviews. The planned merger is expected to broaden the combined product set and customer reach across multiple stages of the life sciences workflow. The Bio-Techne shareholder approval is important, but it should not be the only...

6d agoYahoo Finance

Bio-Techne shareholders approve Merck KGaA acquisition

6d agoInvesting.com

Also Discussed

Investors talking about TECH also mention

#	Name	Attention
1	Alico Inc.ALCO	0%0
2	The E.W. Scripps Company Class A Common StockSSP	0%0
3	MBT - Mobile TeleSystems Public Joint Stock Company	——
4	MRC - MRC Global Inc.	——
5	First Trust Natural Gas ETFFCG	0%0
6	Procore Technologies Inc.PCOR	0%new
7	Grayscale Bitcoin Adopters ETFBCOR	0%new
8	WisdomTree Global ex-U.S. Quality Dividend Growth FundDNL	0%new
9	Primoris Services CorporationPRIM	0%0
10	FGEN - FibroGen, Inc.	——

Bio-Techne Corp.

Healthcare
Biotechnology

Bio-Techne Corp. is a global life sciences company that develops, manufactures, and sells reagents, analytical instruments, and precision diagnostics for research, diagnostic, and bioprocessing applications. Its portfolio supports workflows across basic research, translational science, and clinical decision-making, serving customers in academic laboratories, biotechnology and pharmaceutical development, and diagnostic settings. The company’s products include proteins, antibodies, immunoassays, ELISA kits, molecular diagnostics, spatial biology tools, and specialized instruments used to detect, measure, and analyze biological activity. Bio-Techne also provides custom services such as antibody development, protein degradation solutions, gene engineering, and cell and gene therapy-related services. Through its Protein Sciences and Diagnostics and Spatial Biology businesses, Bio-Techne plays an important role in enabling scientific discovery, biomarker analysis, and laboratory testing across the global healthcare and life sciences market.

Website

Location

614 McKinley Place N.E.

Minneapolis, MN, 55413

United States

Social

What share of all stock conversation is about TECH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% new	0% 0

Jan 30

$TECH stock has surged by 3% to a new high of $500, marking its first major victory.
The article explains the recent news and developments about $TECH in a simple and easy-to-understand format.
The stock's significant increase has brought joy and excitement to investors, with some even calling it a "大発見" (big discovery).

Generated by AI

Sentiment

Of the messages about TECH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	59.69% +4.4
Bearish	—	—	—	40.31% -4.4

Jul 25

TECH has broken above its 150 EMA with strong volume, indicating a potential uptrend.
Bio-Techne Corporation, the owner of the TECH ticker, has a history of significant price increases, suggesting a possible repeat performance.
With a bounce off recent lows and a manageable downside risk, TECH presents a relatively low-risk entry point for a potential long-term run.

Generated by AI

Topics

Of the messages about TECH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	1.32%
Announcements	—	—	—	81.44%
Controversies	—	—	—	0.13%
Earnings	—	—	—	1.8%
Macro	—	—	—	3.78%
Technical Analysis	—	—	—	11.52%

Feb 2

Bio-Techne Corporation's $TECH has no utility in bioweapon development, according to a study using OpenAI's GPT-4.
FBI Director warns that Beijing-linked hackers are targeting US infrastructure, with low blows against civilians part of China's plan.
No market-relevant announcements were found in the provided social media posts.

Generated by AI

Community

Of the messages about TECH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	85.71%	19.02%
Newcomers	—	0%	14.29%	80.98%

Regulars· May 1

Bio-Techne Corporation's shares surged 17.58% after the company released its third-quarter fiscal 2024 results, with the stock trading 121% above average volume.
The results were mixed, with the company's earnings showing a decline due to market challenges, but the stock still saw a significant increase in price.
Bio-Techne Corporation's shares continued to trade above average volume, with the stock up 16.29% after the company's Q3 fiscal 2024 earnings release.

Newcomers· Jan 30

Newcomers to the stock market are finding $TECH's recent 3% increase in price to be a significant win, with one user expressing joy and excitement over the news.
Many users are discovering and sharing articles that explain $TECH's news in simple terms, making it easier for newcomers to understand the company and its stock.
One user has made a big discovery, finding that $TECH's stock price has increased by 3% to 500, and is calling it their first big win in the stock market.

Generated by AI

Bio-Techne

Social

Jan 30

Jul 25

Feb 2

Regulars· May 1

Newcomers· Jan 30

2 Cash-Producing Stocks Worth Investigating and 1 We Brush Off

Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package

Robert V Baumgartner Exercises Options, Realizes $754K - Bio-Techne (NASDAQ:TECH)

Is Bio-Techne Stock Outperforming the Nasdaq?

Merck KGaA (XTRA:MRK) Clears Key Acquisition Hurdle After Shareholder Approval

Bio-Techne shareholders approve Merck KGaA acquisition

Also Discussed

Bio-Techne Corp.

Company Information

Location

2 Cash-Producing Stocks Worth Investigating and 1 We Brush Off

Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package

Robert V Baumgartner Exercises Options, Realizes $754K - Bio-Techne (NASDAQ:TECH)

Is Bio-Techne Stock Outperforming the Nasdaq?

Merck KGaA (XTRA:MRK) Clears Key Acquisition Hurdle After Shareholder Approval

Bio-Techne shareholders approve Merck KGaA acquisition

Also Discussed

Social

Jan 30

Jul 25

Feb 2

Regulars· May 1

Newcomers· Jan 30